EP Patent

EP3157932B1 — Sodium (2r, 5s, 13ar) -7, 9-dioxo-10- ( (2,4,6-trifluorobenzyl) carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13a-octahydro-2, 5-methanopyrido [1',2' : 4.5]pyrazino [2, 1-b]oxazepin-8-olate

Assigned to Gilead Sciences Inc · Expires 2018-01-10 · 8y expired

What this patent protects

Patent listed against bictegravir-sodium.

Drugs covered by this patent

bictegravir-sodium (BICTEGRAVIR SODIUM)

Patent Metadata

Patent number: EP3157932B1
Jurisdiction: EP
Classification: —
Expires: 2018-01-10
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.